Navigation Links
Watson Confirms Renvela® for Oral Suspension Patent Challenge
Date:7/12/2010

MORRISTOWN, N.J., July 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market sevelamer carbonate for oral suspension, 0.8g and 2.4g per packet.  Watson's sevelamer carbonate for oral suspension product is the generic version of Genzyme's Renvela® for Oral Suspension.  Renvela ® is a phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease who are on dialysis.

Genzyme Corporation filed suit against Watson on July 9, 2010 in the United States District Court for the District of Maryland seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent No. 5,667,775.  Genzyme's suit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA for up to 30 months or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.  Based on available information, Watson believes it may be a first applicant to file an ANDA requesting approval of a generic version of Renvela®  for oral suspension, and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity for this dosage form.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts and FDA approvals or actions, if any; the difficulty of predicting the timing or outcome of litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31, 2009 and Watson's quarterly report on Form 10-Q for the period ended March 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Renvela® is a registered trademark of Genzyme Corporation.

(Logo:  http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson to Host Conference Call and Webcast to Discuss Second Quarter 2010 Earnings
2. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
3. Watsons Generic Prograf® 5 mg Receives FDA Approval
4. Watson Launches Generic Exelon®
5. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
6. Watson to Present at the Wells Fargo Securities 2010 Healthcare Conference
7. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line
8. Watsons Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval
9. Watson Launches Generic Version of LIPITOR® in Canada
10. Watson to Present at the 2010 Citi Investment Research Global Healthcare Conference
11. Watson Reaches Settlement with Teva Over Seasonale(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... - bioLytical lanza el INSTI HIV Self Test ... Continue Reading ... New: ... , , bioLytical Laboratories (la "Compañía"), ... está expandiendo el lanzamiento de su INSTI HIV Self Test  a África con ...
(Date:12/2/2016)... held the largest share in the ECG Cables And ... demand for remote monitoring ECG devices. On the other hand, ... to witness the highest growth rate during the forecast period. ... Dickinson and Company (U.S.), Medtronic plc ( Ireland ... and Mindray Medical International Limited ( China ), ...
(Date:12/2/2016)... 2016 Research and Markets has announced the ... and Demand Forecast to 2022" report to their offering. ... , , ... 2015, and it is expected to grow at a CAGR of 5.5% ... witness faster growth during the forecast period, a CAGR of 8.8% in ...
Breaking Medicine Technology:
(Date:12/2/2016)... NY (PRWEB) , ... December 02, 2016 , ... More ... school and while 84 percent of parents report speaking with their child about sex ... and sexually transmitted diseases. , Mediaplanet is proud to announce the launch of its ...
(Date:12/2/2016)... ... 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year old ... purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent ... in several ShopRite and FoodTown stores in NJ and received rave comments from consumers. ...
(Date:12/2/2016)... ... 02, 2016 , ... On November 24th, 2016, Thanksgiving morning, ... different sites throughout Miami-Dade and Broward counties. This is the largest meal delivery ... Thanksgiving morning by putting together individual meals via assembly lines and passing them ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... offer a comprehensive in-house dental plan for all patients. Understanding that budget can ... that gives patients a number of perks, including discounts on many valuable dental ...
(Date:11/30/2016)... Cambridge, MA (PRWEB) , ... November 30, 2016 ... ... care for treating injured workers have been a focus of public policymakers and ... Workers Compensation Research Institute (WCRI) released its Medical Price Index for Workers’ ...
Breaking Medicine News(10 mins):